PREDICT. ENGINEER. OUTCOMPETE PATHOGENS.
Embedded Files
We redesign natural bacterial-produced nanoparticles, called tailocins, into precise and potent drug candidates that treat antibiotic-resistant infections.
Cartoon of a natural tailocin. Our software-in-development redesigns this natural nanotech into a precision antibiotic
Tailocins are nature's nanotech used by bacteria to outcompete their close kin
Our IP-protected, AI-powered platform redesigns tailocins for their subsequent development into safe and effective precision drugs
Elakistos feature by NtbkLM.wavLooking to partner with us?
Get in touch: info@elakistosbiosciences.com
Endorsements
Elakistos Biosciences was one of the start-ups selected to present a tech talk at the NEXT.BIO Conference at University of California San Francisco in October 2025
Elakistos Biosciences was one of Bpifrance EuroQuity's top deeptech start-ups selected for their April 2025 SEADE DEEPTECH E-PITCH.
Check out our 5-min pitch in the youtube video link found here
Elakistos Biosciences is among the few selected AI+Biotech start-ups in the June 2025 cohort of the global and insight-filled Next Sequence accelerator program
Elakistos Biosciences was awarded the best scientific research in the National Research Fund 2024 Kenya National Research Festival Poster Category.
Resources
bioRxiv 2025.04.19.648921; doi: https://doi.org/10.1101/2025.04.19.648921
BMC Genomics 25, 1087 (2024). https://doi.org/10.1186/s12864-024-10858-2
Access Microbiology 5, 10 (2023); https://doi.org/10.1099/acmi.0.000659.v3.
Access Microbiology. 5, 5 (2023); https://doi.org/10.1099/acmi.0.000531.v4.
Front Microbiol. 13, 993688 (2022) doi: 10.3389/fmicb.2022.993688.
Page updated
Report abuse